08.10 07:48 | dpa-AFX: ANALYSE-FLASH: Goldman hebt Ziel für Astrazeneca auf 16046 Pence - 'Buy' |
08.10 07:48 | dpa-AFX: Goldman hebt Ziel für Astrazeneca auf 16046 Pence - 'Buy' |
08.10 07:16 | dpa-AFX: *GOLDMAN RAISES ASTRAZENECA PRICE TARGET TO 16046 (15914) PENCE - 'BUY' |
08.10 07:16 | dpa-AFX: *GOLDMAN HEBT ZIEL FÜR ASTRAZENECA AUF 16046 (15914) PENCE - 'BUY' |
07.10 14:37 | dpa-AFX: AstraZeneca Signs Licence Agreement To Develop CSPC Pharma's Lipid Lowering Pre-clinical Asset |
07.10 14:00 | dpa-AFX: *ASTRAZENECA AND CSPC PHARMA SIGN LICENSE AGREEMENT FOR NOVEL LIPOPROTEIN DISRUPTOR DEVELOPMENT |
07.10 13:17 | dpa-AFX: AstraZeneca Reports Positive Results From BATURA Phase IIIb Trial |
07.10 13:10 | dpa-AFX: *ASTRAZENEC REPORTS POSITIVE RESULTS FROM BATURA PHASE IIIB TRIAL |
07.10 12:04 | Astrazeneca schließt Lizenz-Deal über bis zu 2 Mrd Dollar |
03.10 14:38 | dpa-AFX: AstraZeneca's Calquence Gets Priority Review In US For Patients With Untreated Mantle Cell Lymphoma |
03.10 13:54 | dpa-AFX: *ASTRAZENECA'S CALQUENCE RECEIVES PRIORITY REVIEW FOR UNTREATED MANTLE CELL LYMPHOMA IN U.S. |
03.10 07:14 | dpa-AFX: ANALYSE-FLASH: Jefferies senkt Ziel für Astrazeneca auf 11400 Pence - 'Hold' |
03.10 07:14 | dpa-AFX: Jefferies senkt Ziel für Astrazeneca auf 11400 Pence - 'Hold' |
03.10 05:55 | dpa-AFX: *JEFFERIES SENKT ZIEL FÜR ASTRAZENECA AUF 11400 (11700) PENCE - 'HOLD' |
03.10 05:55 | dpa-AFX: *JEFFERIES CUTS ASTRAZENECA PRICE TARGET TO 11400 (11700) PENCE - 'HOLD' |
02.10 22:44 | dpa-AFX: Arcus Announces Clinical Trial Collaboration With AstraZeneca To Evaluate Casdatifan |
02.10 22:13 | dpa-AFX: *ARCUS, ASTRAZENECA TO EVALUATE COMBINATION MOLECULES FOR CLEAR CELL RENAL CELL CARCINOMA TREATMENT |
01.10 13:05 | dpa-AFX: *ASTRAZENECA AND DAIICHI SANKYO:ENHERTU GRANTED PRIORITY REVIEW IN US FOR HER2-LOW/HER2-ULTRALOW METASTATIC BREAST CANCER |
01.10 08:29 | dpa-AFX: Daiichi Says Enhertu Gets Priority Review In US In HER2 Low/HER2 Ultralow Metastatic Breast Cancer |
01.10 08:05 | dpa-AFX: *DAIICHI: ENHERTU GRANTED PRIORITY REVIEW IN U.S. FOR HER2 LOW OR HER2 ULTRALOW METASTATIC BREAST CANCER |
|